Business Wire

EdiGene Obtains Worldwide License from Boston Children’s Hospital to Methods and Compositions for Increasing Fetal Hemoglobin Levels to Treat Hemoglobinopathies

BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)--EdiGene, Inc., a global biotechnology company focused on translating gene-editing technologies into transformative therapies for patients with serious ...
FOX59 News

The World's First Clinical Base Editing Therapy for Hemoglobinopathy

CorrectSequence Therapeutics' CS-101 Successfully Cures One Patient of Transfusion-Dependent β-Thalassemia Compared with other CRISPR-based β-thalassemia gene editing therapies, CS-101 using tBE ...
manilatimes

Fulcrum Therapeutics Announces Results from the 12 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease

― Robust and clinically meaningful absolute mean fetal hemoglobin (HbF) induction of 8.6% from baseline at 12 weeks of treatment; 7 of 16 patients achieved absolute HbF levels greater than 20% ― ― ...
Morningstar

Editas Medicine Reports New In Vivo Data Highlighting the Potential of Editas’ Gene Upregulation Strategy in HSCs at the American Society of Gene and Cell Therapy Annual Meeting

Data demonstrate therapeutically relevant editing levels using a clinically validated strategy, supporting its development as a novel, in vivo approach to treating sickle cell disease and beta ...
JSTOR Daily

Allosteric control of hemoglobin S fiber formation by oxygen and its relation to the pathophysiology of sickle cell disease

The pathology of sickle cell disease is caused by polymerization of the abnormal hemoglobin S upon deoxygenation in the tissues to form fibers in red cells, causing them to deform and occlude the ...